https://diabetes.acponline.org/archives/2015/10/09/7.htm. The FDA on Sept. 10 released a strengthened warning on canagliflozin (Invokana, Invokamet) about increased risk of bone fractures and decreased ... The FDA on Sept. 10 released a strengthened
Sodium-glucose cotransporter-2 (SGLT2) inhibitors, including canagliflozin, dapagliflozin, and empagliflozin, may cause ketoacidosis, the FDA recently warned. ... The FDA recommend clinicians discontinue SGLT2 inhibitors if acidosis is confirmed and take
The FDA has approved insulin lispro injection (Admelog) to improve glucose control in patients ages three years and older with type 1 diabetes and adult patients with type 2 diabetes, the ... The most common adverse reactions are hypoglycemia, itching,
The FDA on June 11 announced another recall of metformin due to excess levels of N-nitrosodimethylamine (NDMA).
One glucose meter was recalled due to having an incorrect factory-set unit of measure, the FDA announced on April 21.
The FDA has approved ertugliflozin, a sodium-glucose cotransporter-2 (SGLT2) inhibitor, as an adjunct to diet and exercise for adult patients with type 2 diabetes, as of Dec. ... The most common adverse reaction is female genital mycotic infections. The
Invokana, Invokamet), according to an FDA safety alert. ... An ongoing clinical trial found an increase in leg and foot amputations, mostly affecting the toes, in patients treated with canagliflozin (Invokana, Invokamet), according to an FDA safety alert.
25. Insulin degludec injection (Tresiba) and insulin degludec/insulin aspart injection (Ryzodeg 70/30) were approved by the FDA on Sept. ... Both drugs are contraindicated for patients with diabetic ketoacidosis, according to an FDA.
recalls at this time. The FDA recently reported that no sample of metformin that it has tested exceeded the acceptable daily intake for N-nitrosodimethylamine (NDMA), a probable carcinogen. ... The FDA has not recommended metformin recalls in the U.S.
The FDA on Dec. 13, 2019, authorized marketing of the Tandem Diabetes Care Control-IQ Technology, the first interoperable, automated glycemic controller.